Impact of COVID-19 on Health Economics and Technology of Diabetes Care: Use Cases of Real-Time Continuous Glucose Monitoring to Transform Health Care During a Global Pandemic.
Sandip Garg,Gregory J. Norman +1 more
TLDR
In this article, the authors reviewed recent topical literature and COVID-19-related analyses in the public health, health technology, and health economics fields in addition to databases and surveys from government sources and the private sector.Abstract:
Background: The coronavirus disease 2019 (COVID-19) pandemic has exposed vulnerabilities and placed tremendous financial pressure on nearly all aspects of the U.S. health care system. Diabetes care is an example of the confluence of the pandemic and heightened importance of technology in changing care delivery. It has been estimated the added total direct U.S. medical cost burden due to COVID-19 to range between $160B (20% of the population infected) and $650B (80% of the population infected) over the course of the pandemic. The corresponding range for the population with diabetes is between $16B and $65B, representing between 5% and 20% of overall diabetes expenditure in the United States. We examine the evidence to support allocating part of this added spend to infrastructure capabilities to accelerate remote monitoring and management of diabetes. Methods and Results: We reviewed recent topical literature and COVID-19-related analyses in the public health, health technology, and health economics fields in addition to databases and surveys from government sources and the private sector. We summarized findings on use cases for real-time continuous glucose monitoring in the community, for telehealth, and in the hospital setting to highlight the successes and challenges of accelerating the adoption of a digital technology out of necessity during the pandemic and beyond. Conclusions: One critical and lasting consequence of the pandemic will be the accelerated adoption of digital technology in health care delivery. We conclude by discussing ways in which the changes wrought by COVID-19 from a health care, policy, and economics perspective can add value and are likely to endure postpandemic.read more
Citations
More filters
Journal ArticleDOI
Real-Time Continuous Glucose Monitoring During the Coronavirus Disease 2019 Pandemic and Its Impact on Time in Range.
TL;DR: In this article, the authors examined data from 65,067 U.S.-based users of the G6 rtCGM System (Dexcom, Inc., San Diego, CA) who had uploaded data before and during the COVID-19 pandemic.
Journal ArticleDOI
Telemedicine for the Clinical Management of Diabetes; Implications and Considerations After COVID-19 Experience
TL;DR: In this article , a review of telemedicine application in type 1 and type 2 diabetic individuals during the COVID-19 pandemic is presented, and future perspectives for tele-medical use to manage diabetes are discussed.
Journal ArticleDOI
Digital technologies in the care of people with diabetes during the COVID-19 pandemic: a scoping review
Francisca Diana da Silva Negreiros,Açucena Leal de Araújo,Samuel Miranda Mattos,Tatiana Rebouças Moreira,Virna Ribeiro Feitosa Cestari,Lucilane Maria Sales da Silva,Thereza Maria Magalhães Moreira +6 more
TL;DR: In this article, a scoping review of the use of digital technologies in the care of people with diabetes during the COVID-19 pandemic is presented, based on the JBI manual, which includes scientific articles and gray literature from nine primary and seven secondary databases.
Journal ArticleDOI
COVID-19 Pandemic and Diabetes Care.
Satish K. Garg,Erika Rodriguez +1 more
TL;DR: Garg et al. as discussed by the authors presented the second year of the COVID-19 pandemic and discussed the need for a booster for the mRNA vaccines, or if they should only be given to the elderly, those who are immune compromised, and high risk individuals.
References
More filters
Journal ArticleDOI
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Fei Zhou,Ting Yu,Ronghui Du,Guohui Fan,Ying Liu,Zhibo Liu,Jie Xiang,Yeming Wang,Bin Song,Xiaoying Gu,Xiaoying Gu,Lulu Guan,Yuan Wei,Li Hui,Xudong Wu,Jiuyang Xu,Shengjin Tu,Yi Zhang,Hua Chen,Bin Cao +19 more
TL;DR: Wang et al. as discussed by the authors used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death, including older age, high SOFA score and d-dimer greater than 1 μg/mL.
Journal ArticleDOI
The socio-economic implications of the coronavirus pandemic (COVID-19): A review.
Maria Nicola,Zaid Alsafi,Catrin Sohrabi,Ahmed Kerwan,Ahmed Al-Jabir,Christos Iosifidis,Maliha Agha,Riaz Agha +7 more
TL;DR: The socio-economic effects of COVID-19 on individual aspects of the world economy are summarised to show the need for medical supplies has significantly increased and the food sector has seen a great demand due to panic-buying and stockpiling of food products.
Journal ArticleDOI
Economic costs of diabetes in the US in 2002.
TL;DR: In this paper, the authors estimated the direct medical and indirect productivity-related costs attributable to diabetes and calculated and compared the total and per capita medical expenditures for people with and without diabetes.
Journal ArticleDOI
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes.
Lihua Zhu,Zhi-Gang She,Xu Cheng,Juan Juan Qin,Xiao Jing Zhang,Jingjing Cai,Fang Lei,Haitao Wang,Jing Xie,Wenxin Wang,Haomiao Li,Peng Zhang,Xiaohui Song,Xi Chen,Xiang Mei,Chaozheng Zhang,Liangjie Bai,Da Xiang,Ming Ming Chen,Yanqiong Liu,Youqin Yan,Mingyu Liu,Weiming Mao,Jinjing Zou,Liming Liu,Guohua Chen,Pengcheng Luo,Bing Xiao,Changjiang Zhang,Zixiong Zhang,Zhigang Lu,Junhai Wang,Haofeng Lu,Xigang Xia,Daihong Wang,Xiaofeng Liao,Gang Peng,Ping Ye,Jun Yang,Yufeng Yuan,Xiaodong Huang,Jiao Guo,Bing Hong Zhang,Hongliang Li +43 more
TL;DR: Clinical evidence correlating improved glycemic control with better outcomes in patients with COVID-19 and pre-existing T2D is provided, associated with markedly lower mortality compared to individuals with poorly controlled BG during hospitalization.
Journal ArticleDOI
Diabetes is a risk factor for the progression and prognosis of COVID-19.
Weina Guo,Mingyue Li,Yalan Dong,Haifeng Zhou,Zili Zhang,Chunxia Tian,Renjie Qin,Haijun Wang,Yin Shen,Keye Du,Lei Zhao,Heng Fan,Shanshan Luo,Desheng Hu +13 more
TL;DR: To figure out whether diabetes is a risk factor influencing the progression and prognosis of 2019 novel coronavirus disease (COVID‐19), a large number of patients with a history of diabetes will be recruited for this study.
Related Papers (5)
General practice's early response to the COVID-19 pandemic
Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science.
Emily A. Holmes,Emily A. Holmes,Rory C. O'Connor,V. Hugh Perry,Irene Tracey,Simon Wessely,Louise Arseneault,Clive Ballard,Helen Christensen,Roxane Cohen Silver,Ian P. Everall,Tamsin Ford,Ann John,Thomas Kabir,Kate King,Ira Madan,Susan Michie,Andrew K. Przybylski,Roz Shafran,Angela Sweeney,Carol M. Worthman,Lucy Yardley,Katherine Cowan,Claire Cope,Matthew Hotopf,Edward T. Bullmore +25 more